EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Localization Matters: Impacts of PEG‐J Localization in Intestinal Levodopa Therapy for Parkinson's Disease

Philipp Klocke iD, Moritz A Loeffler, Idil Cebi iD, Karl-Ernst Grund, Christine Daniels, Jens Volkmann, Jiri Koschel, Wolfgang H Jost iD, Kazimierz Logmin, Lars Wojtecki, Christoph R Werner, Daniel Weiss iD

Movement Disorders Clinical Practice · 2025

DOI: 10.1002/mdc3.14352 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Movement Disorders Clinical Practice, 2025. Verfasst von Philipp Klocke und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Neurology, Department for Neurodegenerative Diseases, and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, …. Hauptthemen laut MEDLINE: Levodopa, Parkinson Disease, Carbidopa, Antiparkinson Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Real‐world clinical evidence is missing to understand the resorption characteristics of levodopa through duodenal and jejunal parts of the small intestine.

Objective

To characterize how different application sites of intestinal levodopa gel would impact on levodopa dosing and clinical outcomes.

Methods

This multicentre retrospective analysis investigated Parkinson's disease patients (n = 111) and their change in levodopa equivalent dosage when switching from oral treatment to intestinal continuous infusion therapy while stratifying for differences in percutaneous gastrojejunostomy (PEG‐J) tube localizations. We analyzed data from patients treated with both levodopa–carbidopa (LCIG) and levodopa–carbidopa–entacapone (LECIG) intestinal gel.

Results

In dichotomic analysis, duodenal and jejunal tube positions showed similar levodopa equivalent dosages changes from baseline ( P = 0.143). This was similar when subdividing patients for LCIG and LECIG treatment. In duodenal PEG‐J positions, 44.4% of patients showed persistent motor fluctuations compared to 21.9% in jejunal placements ( P = 0.026). In duodenal positions, fluctuations most often persisted when the PEG‐J tube was placed proximally into the duodenum. In jejunal localizations, several patients displayed a satisfactory outcome from the primary intervention but experienced dislocation of the PEG‐J tube to a duodenal position. This was associated with re‐emergence of motor fluctuations in a majority of them.

Conclusions

Our real‐world data suggest that LCIG and LECIG are absorbed similarly in both duodenal and jejunal portions of the small intestine. However, clinical data suggest, that jejunal positioning is critical to the stabilization of dopaminergic motor fluctuations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevodopaParkinson DiseaseCarbidopaAntiparkinson AgentsCatecholsGastric BypassHumansMaleFemaleAgedRetrospective StudiesMiddle AgedDrug CombinationsDuodenumJejunumNitriles

Stichwörter der Autor:innen

LCIGLECIGParkinson's diseaseduodenaljejunal

Substanzen

LevodopaCarbidopaAntiparkinson Agentscarbidopa, levodopa drug combinationDrug CombinationsCatecholsNitrilesentacapone

Autor:innen und Institutionen

  • Centre for Neurology, Department for Neurodegenerative Diseases, and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
  • Centre for General Surgery, Department for Surgical Endoscopy, University Medical Centre Tübingen, Tübingen, Germany.
  • Department of Neurology, University Hospital and Julius-Maximilians-University, Würzburg, Germany.
  • Parkinson-Klinik Ortenau, Wolfach, Germany.
  • Department of Neurology and Neurorehabilitation, Hospital Zum Heiligen Geist, Academic Teaching Hospital of the Heinrich-Heine-University Düsseldorf, Kempen, Germany.
  • Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.

ORCID-Profile: Philipp Klocke, Idil Cebi, Wolfgang H Jost, Daniel Weiss

Zitieren

APA

Klocke, P., Loeffler, M. A., Cebi, I., Grund, K. E., Daniels, C., Volkmann, J., Koschel, J., Jost, W. H., Logmin, K., Wojtecki, L., Werner, C. R., & Weiss, D. (2025). Localization Matters: Impacts of PEG‐J Localization in Intestinal Levodopa Therapy for Parkinson's Disease. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.14352

Vancouver

Klocke P, Loeffler MA, Cebi I, Grund KE, Daniels C, Volkmann J, et al. Localization Matters: Impacts of PEG‐J Localization in Intestinal Levodopa Therapy for Parkinson's Disease. Movement Disorders Clinical Practice. 2025. doi:10.1002/mdc3.14352

BibTeX
@article{Klocke2025,
  author = {Klocke, Philipp and Loeffler, Moritz A and Cebi, Idil and Grund, Karl-Ernst and Daniels, Christine and Volkmann, Jens and Koschel, Jiri and Jost, Wolfgang H and Logmin, Kazimierz and Wojtecki, Lars and Werner, Christoph R and Weiss, Daniel},
  title = {Localization Matters: Impacts of PEG‐J Localization in Intestinal Levodopa Therapy for Parkinson's Disease},
  journal = {Movement Disorders Clinical Practice},
  year = {2025},
  doi = {10.1002/mdc3.14352}
}
Kostenlos starten →